Capstone Therapeutics (NASDAQ:CAPS) Posts Quarterly Earnings Results

Posted by Caroline Horne on May 20th, 2026

Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $12.64 million for the quarter. Capstone Therapeutics had a negative net margin of 45.01% and a negative return on equity of 93.49%.

Capstone Therapeutics Stock Up 1.4%

Shares of CAPS opened at $0.31 on Wednesday. The firm has a market cap of $4.41 million, a P/E ratio of -0.08 and a beta of -1.52. Capstone Therapeutics has a 12-month low of $0.26 and a 12-month high of $2.14. The company’s 50-day moving average price is $0.52 and its 200 day moving average price is $0.67. The company has a current ratio of 1.00, a quick ratio of 0.26 and a debt-to-equity ratio of 0.75.

Institutional Trading of Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC bought a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 2.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Report on CAPS

About Capstone Therapeutics

(Get Free Report)

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.